THE University of Dundee is to partner with global biopharmaceutical company Almirall to develop new treatments for severe skin diseases with high levels of unmet medical need.
The collaboration will accelerate the discovery of innovative medicines by bringing together Almirall’s expertise in dermatology with the world-leading work of Professor Alessio Ciulli (inset), from the University’s School of Life Sciences.
Professor Ciulli is a pioneer in the field of proteolysis-targeting chimeras (PROTACs), a new pharmaceutical system with the potential to revolutionise drug discovery.
While most conventional drugs inhibit cellular targets, PROTACs actually destroy them by manipulating the cell’s natural system for clearing unwanted or damaged proteins. They are expected to be broadly applicable to diverse therapeutic areas.
There are many severe skin diseases with a high level of unmet medical need, and the Almirall-Dundee collaboration aims to identify and develop a novel class of medicines that target and degrade the disease-causing proteins.
Professor Ciulli, chair of Chemical Structural Biology at Dundee and an award-winning biochemist said: “We are looking forward to working on this new research collaboration with Almirall and excited to partner with one of the world-leading companies in the therapeutic area of dermatology. We will work together to advance a next-generation of first-in-class degraders as pharmaceutical agents. These will eliminate protein drivers of disease to ultimately benefit patients.”
“This partnership is an example of how world class university researchers and the pharmaceutical industry can work together to accelerate drug discovery and improve patients’ lives by transformative medicines,” said Dr Thomas Huber, research director at Almirall.
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here